
Jul 7, 2026
Exclusive: How a Swiss pharma got to Octozi's cap table before any US VC did — TFN
Octozi has successfully secured $3 million in seed funding, primarily driven by Swiss pharmaceutical investment, marking a notable deviation from the typical funding trajectory of US healthtech AI startups.The funding round was led by Surface Ventures, with Remarkable Ventures participating alongside an earlier investment from Debiopharm’s venture arm. This early involvement from Debiopharm, particularly prior to engaging US investors, provided Octozi with valuable insights into European pharma'









